Treace Medical Concepts Inc (NAS:TMCI)

$ 7.9 -0.02 (-0.25%) Market Cap: 493.39 Mil Enterprise Value: 481.34 Mil PE Ratio: 0 PB Ratio: 4.69 GF Score: 51/100

Q3 2024 Treace Medical Concepts Inc Earnings Call Transcript
Nov 05, 2024

$5.76 (+6.08%)

Earnings
Q2 2024 Treace Medical Concepts Inc Earnings Call Transcript
Aug 06, 2024

$6.66 (+5.21%)

Earnings
Q1 2024 Treace Medical Concepts Inc Earnings Call Transcript
May 07, 2024

$11.12 (-0.80%)

Earnings
Q4 2023 Treace Medical Concepts Inc Earnings Call Transcript
Feb 27, 2024

$14.38 (+0.35%)

Earnings
Treace Medical Concepts Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Treace Medical Concepts Inc Earnings Call Transcript
Nov 09, 2023

$10 (-6.72%)

Earnings
Treace Medical Concepts Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Treace Medical Concepts Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 16, 2023
Q2 2023 Treace Medical Concepts Inc Earnings Call Transcript
Aug 08, 2023

$20.13 (-2.94%)

Earnings
Treace Medical Concepts Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Treace Medical Concepts Inc Earnings Call Transcript
May 08, 2023

$25.97 (-1.89%)

Earnings
Q4 2022 Treace Medical Concepts Inc Earnings Call Transcript
Mar 07, 2023

$20.23

Earnings
Treace Medical Concepts Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Treace Medical Concepts Inc Earnings Call Transcript
Nov 08, 2022

$20.45 (-2.99%)

Earnings
Treace Medical Concepts Inc To Host Surgeon Advisor Event Call Transcript
Sep 20, 2022
Treace Medical Concepts Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 Treace Medical Concepts Inc Earnings Call Transcript
Aug 09, 2022

$18.57 (-5.78%)

Earnings
Q1 2022 Treace Medical Concepts Inc Earnings Call Transcript
May 05, 2022

$18.01 (-5.56%)

Earnings
Q4 2021 Treace Medical Concepts Inc Earnings Call Transcript
Mar 03, 2022

$20.41 (-1.31%)

Earnings
Treace Medical Concepts Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Q3 2021 Treace Medical Concepts Inc Earnings Call Transcript
Nov 04, 2021

$24.23 (+0.79%)

Earnings
Treace Medical Concepts Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
Q2 2021 Treace Medical Concepts Inc Earnings Call Transcript
Aug 05, 2021

$28.12 (+0.04%)

Earnings
Q1 2021 Treace Medical Concepts Inc Earnings Call Transcript
May 25, 2021

$28.09 (-0.53%)

Earnings

Treace Medical Concepts Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 03:30PM GMT

Release Date Price: $24.66 (+1.11%)

Transcript 8-K

Robert Justin Marcus

JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Robbie Marcus, the medtech analyst at JPMorgan. Happy to kick off the third day of the conference Treace Medical. I'm going to turn it over to John Treace, the Founder and CEO, and then we'll do a bit of Q&A afterwards. John?

John T. Treace

Treace Medical Concepts, Inc. - CEO, Founder & Director

Thank you, Robbie, and good morning, everybody. We're really excited to be here and have the opportunity to talk about Treace Medical at the JPMorgan Healthcare Conference.

So Treace Medical is a high-growth med tech company, 100% focused on improving outcomes for bunion patients. We pioneered and patented the Lapiplasty 3D Bunion Correction procedure to bring better outcomes to patients suffering from painful lifestyle-limiting bunion deformities. Our business has shown strong momentum since our first commercial sale in 2015, and we recently preannounced 2022 revenues representing growth of 50% over prior year.

As a high-growth rate, high

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.